A significant rise in BP was observed among patients switched from celecoxib to rofecoxib following a formulary change

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1490, 2005-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Incidence of Thrombotic Cardiovascular Events in Patients Taking Celecoxib Compared with Those Taking Rofecoxib: Interim Results from the New Zealand Intensive Medicines Monitoring Programme

By Harrison-Woolrych Mira  

Drug Safety, Vol. 28, Iss. 5, 2005-01 ,pp. : 435-442

Adis International

Access to resources Recommend Favorite

Fewer GI complications with rofecoxib and celecoxib

By  

Inpharma, Vol. 1, Iss. 1240, 2000-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Celecoxib and rofecoxib ADRs compared with meloxicam

By  

Inpharma, Vol. 1, Iss. 1409, 2003-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Celecoxib and rofecoxib: risk of GI bleeding

By  

Inpharma, Vol. 1, Iss. 1318, 2001-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Rofecoxib, valdecoxib and celecoxib are associated with increased risks of myocardial infarction (MI) in patients with rheumatic disease

By  

Reactions Weekly, Vol. 1, Iss. 1179, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite